Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

NCT04469114 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

NCT04346355 ·Status: TERMINATED ·Phase: PHASE2

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

NCT04476979 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia

NCT04750317 ·Status: COMPLETED ·Phase: PHASE2

A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study

NCT04412291 ·Status: UNKNOWN ·Phase: PHASE2

The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

NCT04377750 ·Status: UNKNOWN ·Phase: PHASE4

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

NCT00042588 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

NCT04361032 ·Status: UNKNOWN ·Phase: PHASE3

Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab

NCT04359667 ·Status: UNKNOWN

Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia

NCT04329650 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression

NCT04345445 ·Status: UNKNOWN ·Phase: PHASE3

TOFAcitinib in SARS-CoV2 Pneumonia

NCT04332042 ·Status: UNKNOWN ·Phase: PHASE2

Bevacizumab in Patients With Severe Covid-19

NCT04305106 ·Status: UNKNOWN ·Phase: PHASE3

plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients

NCT04622826 ·Status: UNKNOWN ·Phase: PHASE2

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

NCT04361903 ·Status: UNKNOWN

Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers

NCT04387890 ·Status: UNKNOWN

Virological and Immunological Monitoring in Patients (suspected Of/confirmed With) COVID-19

NCT04904692 ·Status: ACTIVE_NOT_RECRUITING

Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

NCT07089719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

NCT04261426 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia

NCT04334850 ·Status: COMPLETED ·Phase: NA

Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)

NCT04365166 ·Status: UNKNOWN

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

NCT04407689 ·Status: TERMINATED ·Phase: PHASE2

Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

NCT05201625 ·Status: UNKNOWN ·Phase: NA

Treatment of Mycobacterium Xenopi Pulmonary Infection

NCT01298336 ·Status: COMPLETED ·Phase: PHASE3